Overview and Scope
Guillain-Barre syndrome drugs refer to medications administered to manage the symptoms and complications of Guillain-Barre syndrome (GBS), an autoimmune disorder characterized by the immune system attacking the nervous system. These drugs are primarily aimed at modulating the peripheral immune system’s activity to halt the progression of the disease and manage its symptoms.
Sizing and Forecast
The Guillain-Barre syndrome drugs market size has grown strongly in recent years. It will grow from $1.08 billion in 2023 to $1.17 billion in 2024 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to progress in the field of research and development, governmental programs and assistance with regulations, increased focus on neurology and autoimmune diseases, increased focus on reducing healthcare costs, and growth in demand for hospital and clinic services.
The Guillain-Barre syndrome drugs market size is expected to see strong growth in the next few years. It will grow to $1.59 billion in 2028 at a compound annual growth rate (CAGR) of 8.0%. The growth in the forecast period can be attributed to the growing rate of guillain-barre syndrome (GBS) incidence, increasing recognition and recognition rates, growing geriatric population, increasing role of hospital pharmacies and retail pharmacies, and growing demand for oral and parenteral medications. Major trends in the forecast period include the development of new therapies, advancements in diagnostic tools, collaboration between pharmaceutical companies and research institutions, advancements in gene therapy, and advancements in intravenous immunoglobulin therapy.
Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/guillain-barre-syndrome-drugs-global-market-report
Segmentation & Regional Insights
The guillain-barre syndrome drugs market covered in this report is segmented –
1) By Drug Class: Immunoglobulins (IVIG), Corticosteroids, Plasma Exchange
2) By Treatment Type: First-Line Treatment, Adjunctive Or Supportive Treatment
3) By Application: Clinic, Hospital, Other Applications
North America was the largest region in the Guillain-Barre syndrome drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the guillain-barre syndrome drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample_request?id=15581&type=smp
Major Driver Impacting Market Growth
The growing demand for personalized medicine is expected to propel the growth of the Guillain-Barre syndrome drugs market going forward. Personalized medicine refers to tailoring medical treatment to individual characteristics, such as genetics or lifestyle, to optimize effectiveness and minimize adverse effects. The growing demand for personalized medicine is driven by its potential to provide more effective treatments, advancements in genomics, increasing disease complexity, and regulatory support. Personalized medicine in Guillain-Barre syndrome (GBS) aims to tailor treatments based on individual patient profiles to improve therapeutic outcomes and reduce adverse effects. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the FDA (Food and Drug Administration), a US-based federal agency, approved 16 novel personalized therapies for patients with rare diseases in 2023, compared to six in 2022. Thus, the increasing demand for personalized medicine is driving the growth of the Guillain-Barre syndrome drugs market.
Key Industry Players
Major companies operating in the guillain-barre syndrome drugs market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Takeda Pharmaceutical Company Limited, Biogen Inc., Chugai Pharmaceutical Co. Ltd., Grifols SA, Octapharma AG, Cadila Healthcare Limited, Argenx SE, Alnylam Pharmaceuticals Inc., Biotest AG, CSL Behring LLC, Kedrion Biopharma Inc., Cellenkos Inc., Annexon Inc., Hansa Medical AB, Akari Therapeutics Plc, Alexion Pharmaceuticals Inc., Vitality Biopharma Inc., CuraVac Inc., Regenesance BV, Cresence AS, Shire Plc
The guillain-barre syndrome drugs market report table of contents includes:
1. Executive Summary
2. Guillain-Barre Syndrome Drugs Market Characteristics
3. Guillain-Barre Syndrome Drugs Market Trends And Strategies
4. Guillain-Barre Syndrome Drugs Market – Macro Economic Scenario
5. Global Guillain-Barre Syndrome Drugs Market Size and Growth
.
.
.
31. Guillain-Barre Syndrome Drugs Market Other Major And Innovative Companies
32. Global Guillain-Barre Syndrome Drugs Market Competitive Benchmarking
33. Global Guillain-Barre Syndrome Drugs Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Guillain-Barre Syndrome Drugs Market
35. Guillain-Barre Syndrome Drugs Market Future Outlook and Potential Analysis
36.Appendix
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
